Next Phase Newsletter

A large corporate’s strategic venture arm is focused on venture and growth stage investments in several verticals including healthcare, IT and energy. The group will make investments from $5M-$30M and is very flexible with structure and size, with approximately 80% of investments in the form of equity and the other 20% in debt. The group will both lead or co-invest and typically seeks board representation although it is not a requirement. The group is focused on companies in the United States, but may look at some international opportunities in select geographies.

The firm is interested in medical devices, healthcare services, digital health, and biopharma and the group is looking for de-risked opportunities in these areas. In the medical device space, the group is interested in devices that have achieved FDA approval and have reimbursement established. Digital health/healthcare IT companies should have commercial traction and a minimum of 10-20 paying customers. The group is looking for healthcare services companies that have proven their business model and are in need of growth capital. In the biopharma space, the group avoids opportunities with binary scientific, development, or clinical risk and is interested in areas such as specialty pharma, outsourced services, platform technologies, etc.

The firm places a large emphasis on high quality management teams and will work with companies with an incomplete management team as long as the key members of management are in place and have significant experience/expertise in the area they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm is a venture capital firm that invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the East Coast has assets under management of about $135M and is investing from its third fund of outside capital, which closed in 2012. The firm invests in technology-enhanced services, and about 80% of the firm’s investments are in digital health technologies. Investments are in the form of equity or (less frequently) convertible debt, and the firm typically invests $500,000-$1.5 M. The firm invests in about 3-4 companies per year, and investments are typically made in Series A rounds. The firm primarily invests in the Northeast and Mid-Atlantic, but will consider investments outside those regions.

The firm invests broadly in the healthcare IT and analytics space, with past investments including a diagnostic platform, consumer wellness apps and health-focused media. They look for companies which provide software and data services to providers, payers, biopharmaceutical firms, and patients. The firm will consider investments related to any indication, but does not consider medical devices or therapeutic drugs. The firm invest only in companies that have fully developed a product.

The firm prefers to invest in companies that have existing revenues, but may consider pre-revenue companies with other strong evidence of their product’s market momentum such as adoption by free users. They like to see recurring revenue, high gross margins, and well-understood customer economics. The firm invests only in privately held companies, but has no other set requirements for management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in California firm invests globally across industries from two active funds, one that is investing primarily in Series A and B rounds, and the other fund is investing in growth stage opportunities. The firm is usually an active lead investor, but may also invest as part of broader syndicates. Typical Series A investments are $5-10M up front with additional capital reserved. The firm supports portfolio companies through entrepreneurial experience, network, and recruiting.

The firm has a strategic focus in life sciences and digital health. Special interest areas include therapeutics (especially platform technologies), digital health (especially products that improve health outcomes), and novel applications of transformative technologies (such as genomics and synthetic biology).

The firm believes passionately that their role is to support and serve great management teams and entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based family office invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies with a typical investment size of $2-10M per company. The firm will generally lead investments, and invests globally with no geographic preference.

The firm is agnostic across life science sectors, including therapeutics, devices, and tools, but will not consider Healthcare IT or digital health technologies. The firm focuses on early stage preclinical to clinical-stage technology, though may be open to commercial-stage technology depending on the opportunity.

The firm is seeking companies with founders who have big ambitions, and a demonstrated ability to sell their team, investors, and partners on their vision. Previous startup experience is a big plus, but not required, and they will invest in young and first-time entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic fund of a large biopharmaceutical group focuses its investment strategy on oncology and infectious diseases. The fund has $150M under management and invests in the range of $1M – $10M per company. The Fund typically seeks to participate in Series A/B rounds, and is currently seeking 1-3 new equity investment opportunities a year. The fund also supports the in-licensing activities of the parent company in the EU and U.S.

The fund is mainly seeking digital health and healthcare IT investment opportunities at pre-commercial or commercial stage that will either improve drug development (e.g. patient recruitment, best responders, combination therapy) or that will impact the patient journey (e.g. patient monitoring, digital therapeutics, clinical decision support systems). In addition the firm considers therapeutic and diagnostic proposals that relate to oncology and infectious diseases. The fund is also seeking oncology and infectious disease therapeutics to in-license. The Fund is agnostic in terms of stage of development.

The fund is very active and supportive with their portfolio companies. The Fund typically seeks a board seat, and at times, also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital fund backed by a family-office makes seed and early-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million of total exposure in any single opportunity. The firm is open to opportunities worldwide but has a preference for domestic investment; the fund currently has portfolio companies in North America, Europe and Oceania.

The first area of focus is Alzheimer’s Disease, where therapeutics (primary), diagnostics (secondary) and other solutions (tertiary) are all valid for consideration. The second area of investment is in technologies that enhance, accelerate, or reduce the cost of clinical trials and basic research, on the broadest scale, beyond Alzheimer’s Disease. This may include hardware and software tools, data analytics or aggregators, or novel approaches to current standards and protocols.

The firm seeks to make early-stage investments, but will also consider later-stage opportunities. The firm’s prior investments include drug discovery for the treatment of Alzheimer’s Disease, a diagnostic to track and recruit patients in early cognitive decline, a tablet-enabled benchtop microscope, an automated imaging tool for micro-dissection of tissue samples, and a platform looking to reinvent the model for pre-human drug testing and development. The fund also has a global partnership to develop intellectual property into potential compound candidates to treat Alzheimer’s Disease.

The firm strongly prefers to invest in privately held companies and will only back top scientists with defendable research, pursuing breakthrough approaches rather than traditional. In their Alzheimer’s portfolio, the fund looks to identify early-stage therapies that have received, and exhausted, non-dilutive sources of funding, such as grants from leading organizations; these companies will ideally be on the radar of large pharma counterparts but looking to obtain additional funds to collect the data required to form pharmaceutical partnerships. In the medical technology sector, the firm prefers to invest in companies developing platform technologies that can demonstrate and defend a clear value proposition addressing the ability to make clinical trials more efficient.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.